Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 0.55 |
| ▸ | EHMT1 | Q9H9B1 | 7/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379114 | 0.99 | HTR4 (0.60) | KDM4EHTR4CYP3A4MEN1ALDH1A1 | |
| SCHEMBL17375500 | 0.92 | KDM4E (0.58) | KDM4EHTR4CYP3A4MEN1ALDH1A1 | |
| SCHEMBL30764768 | 0.92 | KDM4E (0.58) | KDM4EHTR4CYP3A4MEN1ALDH1A1 | |
| SCHEMBL3711173 | 0.90 | LMNA (0.56) | KDM4EHTR4CYP3A4MEN1ALDH1A1 | |
| SCHEMBL3471214 | 0.90 | LMNA (0.56) | KDM4EHTR4CYP3A4MEN1ALDH1A1 | |
| SCHEMBL19260705 | 0.89 | HTR4 (0.56) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| SCHEMBL2926517 | 0.89 | HTR4 (0.56) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| SCHEMBL6336768 | 0.89 | HTR4 (0.62) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL2925147 | 0.88 | HTR4 (0.57) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 | |
| SCHEMBL20028142 | 0.85 | EHMT2 (0.67) | HTR4CYP3A4MEN1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409636-B | Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 沈阳药科大学 | 2023-04-18 | — | — | CN | claimed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10407423-B2 | Compounds as inhibitors of DNA methyltransferases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2019-09-10 | — | — | US | disclosed |
| WO-2019036384-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-3416963-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180362525-A1 | NOVEL COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-12-20 | — | — | US | disclosed |
| EP-3377490-A1 | NOVEL COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2018-09-26 | — | — | EP | disclosed |
| WO-2017142947-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362525-A1 | NOVEL COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | DNMT3B, DNMT3A, DNMT1 | KDM4E 61/4885HTR4 4701/4885CYP3A4 587/4885 |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | KDM4E 42/4885HTR4 3486/4885CYP3A4 4515/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | KDM4E 52/4885HTR4 3234/4885CYP3A4 4215/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | KDM4E 42/4885HTR4 3486/4885CYP3A4 4515/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | KDM4E 52/4885HTR4 3234/4885CYP3A4 4215/4885 |
| US-10407423-B2 | Compounds as inhibitors of DNA methyltransferases | DNMT3B, DNMT3A, DNMT1 | KDM4E 64/4885HTR4 4692/4885CYP3A4 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.